COMP <GO>
LUNG vs KRMD // RSI-14 & 200D SMA MOMENTUM
Pulmonx Corporation (NASDAQ) VS. KORU Medical Systems Inc. (NASDAQ) • 15-METRIC TALLY: LUNG 2
— KRMD 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LUNG
LAST: $3.17 (+25.60%) • MKT CAP: $135.9M
rsi-technicals
77.1
LAST: $3.23 (+0.31%) • MKT CAP: $149.1M
rsi-technicals
42.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LUNG VS. KRMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LUNG | KRMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.20% | 62.30% | +11.90 | LUNG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -28.70% | -6.30 | KRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -24.15% | 0.31% | -24.46 | KRMD | /fcf-yield <GO> |
| Operating Margin | -59.30% | -7.20% | -52.10 | KRMD | /operating-margins <GO> |
| Net Profit Margin | -59.70% | -6.40% | -53.30 | KRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 22.20% | -14.20 | KRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 8.05 | -7.85 | KRMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | KRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 77.1 | 42.1 | +35.04 | LUNG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $135.9M | $149.1M | -$13.2M | KRMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LUNG REV | KRMD REV | LUNG GROSS % | KRMD GROSS % | LUNG FCF | KRMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $90.5M | $41.1M | 74.2% | 62.3% | -$32.8M | $462.4K |
| FY 2024 | $83.8M | $33.6M | 74.0% | 63.4% | -$33.0M | -$319.7K |
| FY 2023 | $68.7M | $28.5M | — | — | -$37.6M | -$4.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LUNG // BETA —
KRMD // BETA —